Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain (Morpheus/DPH)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01495858
First received: December 16, 2011
Last updated: May 16, 2014
Last verified: May 2014
  Purpose

The objective of the study is to evaluate the efficacy and safety of a single oral dose of naproxen sodium 440 mg in combination with DPH (diphenhydramine) 25 mg in subjects with postsurgical dental pain and phase advanced sleep.


Condition Intervention Phase
Pain, Postoperative
Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)
Drug: Naproxen Sodium 440 mg (BAYH6689)
Drug: DPH 50 mg
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Wake Time After Sleep Onset (WASO) Measured by Actigraphy [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    WASO was defined as Total wake time (in minutes) after sleep onset during the 10 hours in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

  • Sleep Latency Measured by Actigraphy [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Sleep latency was defined as the time to sleep onset from the time of dosing as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.


Secondary Outcome Measures:
  • Total Sleep Time Measured by Actigraphy [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Total time spent sleeping (not to exceed 600 minutes) during the in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

  • Sleep Efficiency Measured by Actigraphy [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

  • Global Assessment of Investigational Product as a Sleep Aid [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    The Global Assessment of Investigational Product as a Sleep-Aid was rated using a 5-point categorical scale for which the potential response was poor (0), fair, (1), good (2), very good (3), or excellent (4).

  • Karolinska Sleep Diary - Sleep Quality [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question: How was your sleep? very poor (1); rather poor (2); neither poor nor good (3); rather good (4); very good (5)

  • Karolinska Sleep Diary - Calmness of Sleep [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question: How calm was your sleep? very restless (1); rather restless (2); neither restless nor calm (3); rather calm (4); very calm (5)

  • Karolinska Sleep Diary - Easiness to Fall Asleep [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question: How easy was it to fall asleep? very difficult (1); rather difficult (2); neither difficult nor easy (3); rather easy (4); very easy (5)

  • Karolinska Sleep Diary - Premature Awakening [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question : Premature awakening? woke up much too early (1); woke up somewhat too early (2); no (3)

  • Karolinska Sleep Diary - Ease of Awakening [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question: Ease of awakening? (1) very difficult; (2) rather difficult; (3) neither difficult nor easy; (4) rather easy; very easy (5)

  • Karolinska Sleep Diary - Well Rested [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question: Well Rested? not rested at all (1); somewhat unrested (2); completely rested (3)

  • Karolinska Sleep Diary - Sufficient Sleep [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to the following question: Did you get enough (sufficient) sleep? no, definitely too little (1); no, much too little (2); no, somewhat too little (3); yes, almost enough (4); yes, definitely enough (5)

  • Subjective Sleep Questionnaire - Quality of Your Sleep Last Night [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subject evaluated sleep quality on a 10-point scale, where 1 was poor and 10 was excellent.

  • Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to Refreshing nature of sleep (10-point scale, where 1 was not refreshing and 10 was very refreshing)

  • Subjective Sleep Questionnaire - Time to Fall Asleep Last Night [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to Estimate of how long it took to fall asleep (minutes)

  • Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    Subjects responded to Estimate of the amount of time the subject was awake from the time he or she fell asleep until the time he or she got out of bed (hours and minutes)

  • Change From Baseline in Pain Intensity [ Time Frame: Baseline and up to 10 hours ] [ Designated as safety issue: No ]
    Pain Severity was collected on a 4-point categorical scale: 0=no pain, 1=mild pain, 2=moderate pain, 4=severe pain

  • Overall Rating of Pain Relief [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    The Pain Relief Rating Scale was a 5-point categorical scale which included the following possible responses to the request to finish statement "Overall, the relief from my starting pain was": no relief (0); a little relief (1); some relief (2); a lot of relief (3); complete relief (4).

  • Time to Rescue Medication [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

  • Cumulative Proportion of Participants Taking Rescue Medication by Hour [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

  • Global Assessment of Investigational Product as a Pain Reliever [ Time Frame: Up to 10 hours ] [ Designated as safety issue: No ]
    The Global Assessment of Investigational Product as a Pain Reliever was a 5- point categorical scale which included the following possible responses: poor (0); fair (1); good (2); very good (3); excellent (4).


Other Outcome Measures:
  • Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2 [ Time Frame: Baseline and day 2 ] [ Designated as safety issue: Yes ]
  • Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2 [ Time Frame: Baseline and Day 2 ] [ Designated as safety issue: Yes ]
  • Vital Signs: Mean Change From Baseline in Pulse Rate at Day 2 [ Time Frame: Baseline and day 2 ] [ Designated as safety issue: Yes ]
  • Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2 [ Time Frame: Baseline and day 2 ] [ Designated as safety issue: Yes ]

Enrollment: 267
Study Start Date: December 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)
Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
Active Comparator: Naproxen Sodium 440 mg (BAYH6689) Drug: Naproxen Sodium 440 mg (BAYH6689)
Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
Active Comparator: DPH 50 mg Drug: DPH 50 mg
Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, ambulatory, male and female volunteers ages 12 and older
  • Scheduled to undergo surgical removal of a minimum of two third molars of which at least one has to be a mandibular third molar. The mandibular extraction(s) required by each subject must meet one of the following scenarios:

    • one full bony impaction
    • two partial bony impactions
    • one full bony impaction and one partial bony impaction
    • one full bony impaction and one soft tissue impaction
    • one full bony impaction and one erupted third molar. Two full bony mandibular impactions are not allowed. Maxillary third molars may be removed regardless of impaction level.
  • Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale between 1600 hour and 1830 hour on the day of surgery
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy.

Exclusion Criteria:

  • History of hypersensitivity to naproxen, diphenhydramine, nonsteroidal anti-inflammatory drug (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products
  • Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator
  • Current or past history of bleeding disorder(s)
  • Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator
  • Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months
  • Positive alcohol breathalyzer test and positive urine drug test prior to surgery
  • Females who are pregnant or lactating
  • Chronic or severe sleep problems that do not respond to Over the Counter (OTC) medication and requires a prescription hypnotic or sedative
  • Habitually spends less than 6.5 hours in bed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01495858

Locations
United States, Texas
Austin, Texas, United States, 78744
United States, Utah
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01495858     History of Changes
Other Study ID Numbers: 15881
Study First Received: December 16, 2011
Results First Received: January 24, 2014
Last Updated: May 16, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Bayer:
Naproxen sodium
Diphenhydramine

Additional relevant MeSH terms:
Pain, Postoperative
Pain
Pathologic Processes
Postoperative Complications
Signs and Symptoms
Diphenhydramine
Naproxen
Promethazine
Analgesics
Analgesics, Non-Narcotic
Anesthetics
Anesthetics, Local
Anti-Allergic Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antiemetics
Antipruritics
Antirheumatic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Cyclooxygenase Inhibitors
Dermatologic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Gout Suppressants
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Hypnotics and Sedatives

ClinicalTrials.gov processed this record on November 23, 2014